{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:09:54Z","timestamp":1793912994953,"version":"4.8.0"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To explore the safety and preliminary efficacy of Disitamab Vedotin (DV) combined with Toripalimab (T) and concurrent radiotherapy regimen (DVTR) in the comprehensive bladder-preserving treatment for HER2-positive invasive bladder cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material<\/jats:title>\n                    <jats:p>A total of 10 invasive bladder cancer patients who met the indication for radical cystectomy (RC) but refused the surgery were enrolled from January 2023 to Sep 2025, with follow-up extended until March 2026. All patients underwent maximum transurethral resection of bladder tumor (mTURBT)+\/-neoadjuvant therapy with DV plus T after postoperative pathology confirmed HER2 positivity. Concurrent radiotherapy was administered combined with synchronous DV plus T treatment. Patients were followed up until March 2026 or death after the end of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall treatment completion rate was 90% (9\/10), with 1 patient only receiving 46 Gy of radiotherapy due to personal reasons. The incidence of grade \u22653 adverse reactions during treatment was 10% (1\/10), which was leukopenia. The common grade 1\u20132 adverse reactions were radiation cystitis (9\/10) and hand-foot numbness (2\/10); hemorrhagic cystitis caused by radiation occurred in 2 patients (2\/10) at the 20th and 22nd months after treatment, respectively. At the last follow-up, the median follow-up time was 17.2 months (range, 6\u201331 months). The bladder preservation success rate was 90% (9\/10); the patient who did not complete radiotherapy had T3 recurrence at 5 months, underwent salvage RC and recovered normally, however, died of intestinal obstruction complications 13 months later. The event-free survival rate was 80% (8\/10); 1 patient had T1 recurrence at 7 months after treatment and continued bladder-preserving treatment for 31 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As a novel strategy for comprehensive bladder-preserving treatment, the DVTR regimen based on DV combined with T and concurrent radiotherapy has initially shown acceptable safety and preliminaryly reliable efficacy in this study. It provides a potential bladder-preserving option for patients with HER2-positive invasive bladder cancer regardless of PD-L1 status, though this conclusion requires validation in larger cohorts,which is worthy of further investigation with an expanded sample size.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1880457","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:43:31Z","timestamp":1782895411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive invasive bladder cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Han","family":"Chen","sequence":"first","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xian","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyong","family":"Dai","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangjun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02482","article-title":"Efficacy and safety of disitamab vedotin in patients with HER2-positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II trials","volume":"41","author":"Zhou","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3868","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced urothelial carcinoma: Results of the POLARIS-03 trial","volume":"28","author":"Sheng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: Bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.109515","article-title":"Radiotherapy elicits immunogenic cell death and metabolic shifts in the tumor microenvironment: Implications for immunotherapy","volume":"22","author":"Hang","year":"2025","journal-title":"Int J Med Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-75863-1_18","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1880457\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:43:32Z","timestamp":1782895412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1880457\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":9,"alternative-id":["10.3389\/fonc.2026.1880457"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1880457","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1880457"}}